To Örebro University

oru.seÖrebro University Publications
Change search
Refine search result
1 - 8 of 8
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Carstens, Adam
    Örebro University, School of Medical Sciences.
    Chronic inflammatory bowel diseases: studies of microbiota and its influence2021Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Introduction: Inflammatory bowel diseases are becoming increasingly common. The underlying mechanisms are not entirely known but the gut microbiota seem to be involved in the pathogenesis. 

    Aim: The aim of this thesis was to characterise gut microbiota related to diagnosis, disease course and response to biological treatment, taking aspects of the source of biological material into account. 

    Materials and methods: Patients and healthy individuals from several different cohorts in Sweden and Europe were invited. Faecal samples and mucosal biopsies were analysed using different sequencing platforms to investigate the gut microbiota. In Study I the faecal microbiota was correlated to different inflammatory bowel diseases. In Study II we compared the microbiota in faeces to the microbiota in mucosal biopsies. In StudyIII we related the faecal microbiota to the outcome of biological treatment. In Study IV we investigated the diagnostic and prognostic properties of the GAmapTM Dysbiosis Test.

    Results: The faecal microbiota in collagenous colitis resembles the faecalmicrobiota in inflammatory bowel disease. The faecal microbiota differs from the mucosal microbiota. Faecal microbiota at initiation of biological treatment among patients with Crohn’s disease differ between responders and non-responders. The GAmapTM Dysbiosis Test discriminates patients with inflammatory bowel disease from healthy individuals.

    Conclusion: Collagenous colitis may share microbial underpinnings with other inflammatory bowel diseases. Conclusions about mucosal interactions with the gut microbiota should be made with caution when usingfaecal samples to characterise the microbiota. In Crohn’s disease, the faecal microbiota may be included in a model to predict the outcome of biological treatment. The GAmap Dysbiosis Test does not seem to be superior to other current diagnostic tools in clinical decision-making. 

    List of papers
    1. The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis
    Open this publication in new window or tab >>The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis
    Show others...
    2019 (English)In: Clinical and Translational Gastroenterology, E-ISSN 2155-384X, Vol. 10, no 7, article id e00065Article in journal (Refereed) Published
    Abstract [en]

    INTRODUCTION: In inflammatory bowel disease (IBD), an aberrant immune response to gut microbiota is important, but the role of the microbiota in collagenous colitis (CC) is largely unknown. We aimed to characterize the microbiota of patients with CC compared with that of healthy control and patients with IBD.

    METHODS: Fecal samples were collected from patients with CC (n = 29), age- and sex-matched healthy controls (n = 29), patients with Crohn's disease (n = 32), and patients with ulcerative colitis (n = 32). Sequence data were obtained by 454 sequencing of 16S rRNA gene amplicons, and the obtained sequences were subsequently taxonomically classified.

    RESULTS: Analysis of similarity statistics showed a segregation between patients with CC and healthy controls with increasing taxonomic resolution, becoming significant comparing operational taxonomic unit data (P = 0.006). CC had a lower abundance of 10 different taxa. Taxa-specific analyses revealed a consistent lower abundance of several operational taxonomic units belonging to the Ruminococcaceae family in patients with CC, q < 0.05 after false discovery rate correction. Loss of these taxa was seen in patients with CC with active disease and/or corticosteroid treatment only and resembled the findings in patients with IBD.

    DISCUSSION: CC is associated with a specific fecal microbiome seen primarily in patients with active disease or ongoing corticosteroid treatment, whereas the microbiome of CC patients in remission resembled that of healthy controls. Notably, the shift in key taxa, including the Ruminococcaceae family, was also observed in IBD. There may be common mechanisms in the pathogenesis of CC and IBD.

    Place, publisher, year, edition, pages
    Nature Publishing Group, 2019
    National Category
    Gastroenterology and Hepatology
    Identifiers
    urn:nbn:se:oru:diva-75573 (URN)10.14309/ctg.0000000000000065 (DOI)000478837900001 ()31343467 (PubMedID)2-s2.0-85070852572 (Scopus ID)
    Available from: 2019-08-09 Created: 2019-08-09 Last updated: 2023-12-08Bibliographically approved
    2. Differential clustering of faecal and mucosa-associated microbiota in healthy individuals
    Open this publication in new window or tab >>Differential clustering of faecal and mucosa-associated microbiota in healthy individuals
    Show others...
    2018 (English)In: Journal of Digestive Diseases, ISSN 1751-2972, E-ISSN 1751-2980, Vol. 19, no 12, p. 745-752Article in journal (Refereed) Published
    Abstract [en]

    BACKGROUND: Faecal samples are often used to characterise gut microbiota, since they are easily collected. However, whether or not the faecal microbiota differ from the mucosa-associated microbiota remains largely unknown. This may be specifically relevant in conditions that are characterised by complex mucosal microbe-host interactions, such as Crohn's disease. We aimed to determine the degree of agreement between faecal and mucosal microbiota profiles in healthy individuals, using two commonly used collection procedures.

    MATERIAL AND METHODS: The gut microbiota composition of faecal samples (sent at ambient temperature before storage at -70°C) and of colonic biopsies (obtained at endoscopy and immediately stored at -70°C) was determined by sequencing the 16S rRNA gene. Thirty-one randomly selected healthy individuals from the population-based colonoscopy (Popcol) study were included.

    RESULTS: Faecal samples were characterised by a reduced degree of richness (p<0.0001) and diversity (p=0.016), and also differences in several phyla, including a lower relative abundance of Proteobacteria (p<0.0001) and Verrucomicrobia (p=0.008) than in biopsies. Only 3 of 30 individuals had a similar faecal and mucosal microbiota profile, based on weighted UniFrac analysis. A difference in Crohn's disease dysbiosis-associated bacteria was observed, including a lower relative abundance of Faecalibacterium (p=0.004) and a higher relative abundance of Ruminococcus (p=0.001) in faeces than in biopsies.

    CONCLUSIONS: Analysis of faecal samples that have been transported at ambient temperature does not adequately reflect the colonic mucosa-associated microbiota in healthy individuals. These findings have implications for the interpretation of the previous literature, and may be specifically relevant to studies on Crohn's disease.

    Place, publisher, year, edition, pages
    Wiley-Blackwell Publishing Asia, 2018
    Keywords
    Crohn disease, fecal microbiota, mucosa-associated microbiota
    National Category
    Microbiology in the medical area Gastroenterology and Hepatology
    Identifiers
    urn:nbn:se:oru:diva-70345 (URN)10.1111/1751-2980.12688 (DOI)000455494100004 ()30467977 (PubMedID)2-s2.0-85059893806 (Scopus ID)
    Funder
    Swedish Research Council, 2012-1930 2011-2764
    Note

    Funding Agencies:

    Örebro University  

    Bengt Ihre Foundation  

    Nanna Svartz Foundation  

    Örebro University Hospital Research Foundation  

    Örebro County Research Foundation  

    Söderberg Foundation  

    Swedish Foundation for Gastrointestinal Research 

    Available from: 2018-11-27 Created: 2018-11-27 Last updated: 2021-09-20Bibliographically approved
    3. Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel disease
    Open this publication in new window or tab >>Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel disease
    Show others...
    (English)Manuscript (preprint) (Other academic)
    National Category
    General Practice
    Identifiers
    urn:nbn:se:oru:diva-94459 (URN)
    Available from: 2021-09-20 Created: 2021-09-20 Last updated: 2021-10-22Bibliographically approved
    4. Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
    Open this publication in new window or tab >>Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)
    Show others...
    2020 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 55, no 10, p. 1146-1156Article in journal (Refereed) Published
    Abstract [en]

    Method: We examined faecal samples, using the GA-map (TM) Dysbiosis Test, to associate gut microbiota composition with Crohn's disease (CD) and ulcerative colitis (UC) and to identify markers for future biomarker identification. We conducted a prospective case-control study (EU-ref. no. 305676) in an inception cohort of 324 individuals (64 CD, 84 UC, 116 symptomatic non-IBD controls and 44 healthy controls) across five European centres and examined 54 predetermined bacterial markers. We categorized patients according to the Montreal Classification and calculated the dysbiosis index (DI). Non-parametric tests were used to compare groups and the Bonferroni correction to adjust for multiple comparisons.

    Results: The fluorescent signals (FSSs) for Firmicutes and Eubacterium hallii were lower in inflammatory bowel disease (IBD) vs. symptomatic controls (p<.05). FSS for Firmicutes, Lachnospiraceae, Eubacterium hallii and Ruminococcus albus/bromii were lower, whereas the signal fo rBacteroides Fragilis was higher in UC vs. symptomatic controls (p<.05). FSS was higher for Bifidobacterium spp., Eubacterium hallii, Actinobacteria and Firmicutes among patients with ulcerative proctitis, compared to extensive colitis (p<.05). In CD, we observed no association with disease location. The DI correlated with faecal-calprotectin in both CD and in UC (p<.001). In terms of treatment escalation and anti-TNF response, differences were observed for some bacterial markers, but none of these associations were statistically significant.

    Conclusion: Our data reveal that the GA-map (TM) Dysbiosis Test holds the potential to characterize the faecal microbiota composition and to assess the degree of dysbiosis in new-onset IBD. On the other hand, our results cannot demonstrate any proven diagnostic or predictive value of this method to support clinical decision making.

    Place, publisher, year, edition, pages
    Taylor & Francis, 2020
    Keywords
    Anti-TNF, Crohn's disease, dysbiosis, faecal microbiota, inflammatory bowel disease, prognosis, ulcerative colitis
    National Category
    Gastroenterology and Hepatology
    Identifiers
    urn:nbn:se:oru:diva-85272 (URN)10.1080/00365521.2020.1803396 (DOI)000559692100001 ()32780604 (PubMedID)2-s2.0-85089458576 (Scopus ID)
    Note

    Funding Agency:

    European Union (EU) 2858546

    Available from: 2020-09-02 Created: 2020-09-02 Last updated: 2021-09-20Bibliographically approved
    Download (png)
    Bild
    Download (pdf)
    Cover
    Download (pdf)
    Spikblad
  • 2.
    Carstens, Adam
    et al.
    Örebro University, School of Medical Sciences. Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Björkqvist, Olle
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Lindqvist, Carl Mårten
    Örebro University, School of Medical Sciences.
    Rangel, I.
    Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden.
    Repsilber, Dirk
    Örebro University, School of Medical Sciences.
    Eriksson, Carl
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
    Bresso, F.
    Division of Gastroenterology, Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
    Strid, H.
    Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden.
    Hjortswang, H.
    Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
    Keita, Å.
    Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
    Magnusson, M. K.
    Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
    Hedin, C.
    Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden; Karolinska University Hospital, Gastroenterology unit, Department of Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden.
    Kruse, Robert
    Örebro University, School of Medical Sciences.
    Engstrand, L.
    Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden.
    Carlson, M.
    Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
    Söderholm, J.
    Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Surgery, Linköping University, Linköping, Sweden.
    Öhman, L.
    Department of Microbiology and Immunology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel diseaseManuscript (preprint) (Other academic)
  • 3.
    Carstens, Adam
    et al.
    Örebro University, School of Medical Sciences. Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Dicksved, Johan
    Department of Animal Nutrition and Management, Swedish University of Agricultural Sciences, Uppsala, Sweden.
    Nelson, Ronald
    Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
    Lindqvist, Carl Mårten
    Örebro University, School of Medical Sciences.
    Andreasson, Anna
    Division of Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Sweden.
    Bohr, Johan
    Örebro University, School of Health Sciences. Örebro University Hospital. Department of Gastroenterology.
    Tysk, Curt
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Talley, Nicholas J.
    Faculty of Medicine and Health, University of Newcastle, Newcastle, Australia.
    Agréus, Lars
    Division of Family Medicine and Primary Care, Karolinska Institutet, Huddinge, Sweden.
    Engstrand, Lars
    Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis2019In: Clinical and Translational Gastroenterology, E-ISSN 2155-384X, Vol. 10, no 7, article id e00065Article in journal (Refereed)
    Abstract [en]

    INTRODUCTION: In inflammatory bowel disease (IBD), an aberrant immune response to gut microbiota is important, but the role of the microbiota in collagenous colitis (CC) is largely unknown. We aimed to characterize the microbiota of patients with CC compared with that of healthy control and patients with IBD.

    METHODS: Fecal samples were collected from patients with CC (n = 29), age- and sex-matched healthy controls (n = 29), patients with Crohn's disease (n = 32), and patients with ulcerative colitis (n = 32). Sequence data were obtained by 454 sequencing of 16S rRNA gene amplicons, and the obtained sequences were subsequently taxonomically classified.

    RESULTS: Analysis of similarity statistics showed a segregation between patients with CC and healthy controls with increasing taxonomic resolution, becoming significant comparing operational taxonomic unit data (P = 0.006). CC had a lower abundance of 10 different taxa. Taxa-specific analyses revealed a consistent lower abundance of several operational taxonomic units belonging to the Ruminococcaceae family in patients with CC, q < 0.05 after false discovery rate correction. Loss of these taxa was seen in patients with CC with active disease and/or corticosteroid treatment only and resembled the findings in patients with IBD.

    DISCUSSION: CC is associated with a specific fecal microbiome seen primarily in patients with active disease or ongoing corticosteroid treatment, whereas the microbiome of CC patients in remission resembled that of healthy controls. Notably, the shift in key taxa, including the Ruminococcaceae family, was also observed in IBD. There may be common mechanisms in the pathogenesis of CC and IBD.

  • 4.
    Carstens, Adam
    et al.
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Internal Medicine, Ersta hospital, Stockholm, Sweden.
    Roos, Annika
    Department of Microbiology, Tumor and Cell biology & Science for Life Laboratory, Karolinska Institute, Solna, Sweden.
    Andreasson, Anna
    Department of Microbiology, Tumor and Cell biology & Science for Life Laboratory, Karolinska Institute, Solna, Sweden; Division for Family Medicine, Karolinska Institute, Stockholm, Sweden; Stress Research Institute, Stockholm University, Stockholm, Sweden.
    Magnuson, Anders
    Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Agréus, Lars
    Division for Family Medicine, Karolinska Institute, Stockholm, Sweden.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Engstrand, Lars
    Department of Microbiology, Tumor and Cell biology & Science for Life Laboratory, Karolinska Institute, Solna, Sweden.
    Differential clustering of faecal and mucosa-associated microbiota in healthy individuals2018In: Journal of Digestive Diseases, ISSN 1751-2972, E-ISSN 1751-2980, Vol. 19, no 12, p. 745-752Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Faecal samples are often used to characterise gut microbiota, since they are easily collected. However, whether or not the faecal microbiota differ from the mucosa-associated microbiota remains largely unknown. This may be specifically relevant in conditions that are characterised by complex mucosal microbe-host interactions, such as Crohn's disease. We aimed to determine the degree of agreement between faecal and mucosal microbiota profiles in healthy individuals, using two commonly used collection procedures.

    MATERIAL AND METHODS: The gut microbiota composition of faecal samples (sent at ambient temperature before storage at -70°C) and of colonic biopsies (obtained at endoscopy and immediately stored at -70°C) was determined by sequencing the 16S rRNA gene. Thirty-one randomly selected healthy individuals from the population-based colonoscopy (Popcol) study were included.

    RESULTS: Faecal samples were characterised by a reduced degree of richness (p<0.0001) and diversity (p=0.016), and also differences in several phyla, including a lower relative abundance of Proteobacteria (p<0.0001) and Verrucomicrobia (p=0.008) than in biopsies. Only 3 of 30 individuals had a similar faecal and mucosal microbiota profile, based on weighted UniFrac analysis. A difference in Crohn's disease dysbiosis-associated bacteria was observed, including a lower relative abundance of Faecalibacterium (p=0.004) and a higher relative abundance of Ruminococcus (p=0.001) in faeces than in biopsies.

    CONCLUSIONS: Analysis of faecal samples that have been transported at ambient temperature does not adequately reflect the colonic mucosa-associated microbiota in healthy individuals. These findings have implications for the interpretation of the previous literature, and may be specifically relevant to studies on Crohn's disease.

  • 5.
    Ricanek, P.
    et al.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway.
    Rahul, K.
    University of Edinburgh, Edinburgh, United Kingdom.
    Ber, Y.
    Hospital Clinico Universitario, Zaragoza, Spain.
    Vatn, S.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Finnby, L.
    Genetic Analysis AS, Oslo, Norway.
    Lindahl, T.
    Genetic Analysis AS, Oslo, Norway.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    Carstens, Adam
    Örebro University, School of Medical Sciences.
    Söderholm, J.
    Linköping University, Linköping, Sweden.
    Jahnsen, J.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Gomollon, F.
    Hospital Clinico Universitario, Zaragoza, Spain.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Örebro University Hospital.
    Satsangi, J.
    University of Edinburgh, Edinburgh, United Kingdom.
    Casen, C.
    Genetic Analysis AS, Oslo, Norway.
    Vatn, M. H.
    Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease2017In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 11, no Suppl. 1, p. S483-S484Article in journal (Refereed)
  • 6.
    Vatn, S.
    et al.
    Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Carstens, Adam
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden.
    Kristoffersen, A. B.
    Genetic Analysis AS, Oslo, Norway.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
    Casén, C.
    Genetic Analysis AS, Oslo, Norway.
    Moen, A. E. F.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
    Tannaes, T. M.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Clinical Molecular Biology (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
    Lindstrøm, J.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway; Department of Pediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway.
    Detlie, T. E.
    Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Olbjørn, C.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
    Lindqvist, Carl Mårten
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Söderholm, J. D.
    Digestive Diseases Unit, IIS Aragón, Zaragoza, Spain.
    Gomollón, F.
    Gastrointestinal Unit, Centre for Genomics and Molecular Medicine, Division of Medical and Radiological Sciences, University of Edinburgh, Edinburgh, UK.
    Kalla, R.
    Translational Gastroenterology Unit, Medical Sciences/Experimental Medicine Division, University of Oxford, Oxford, UK.
    Satsangi, J.
    Translational Gastroenterology Unit, Medical Sciences/Experimental Medicine Division, University of Oxford, Oxford, UK.
    Vatn, M. H.
    Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Jahnsen, J.
    Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Ricanek, P.
    Department of Gastroenterology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway.
    Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character)2020In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708, Vol. 55, no 10, p. 1146-1156Article in journal (Refereed)
    Abstract [en]

    Method: We examined faecal samples, using the GA-map (TM) Dysbiosis Test, to associate gut microbiota composition with Crohn's disease (CD) and ulcerative colitis (UC) and to identify markers for future biomarker identification. We conducted a prospective case-control study (EU-ref. no. 305676) in an inception cohort of 324 individuals (64 CD, 84 UC, 116 symptomatic non-IBD controls and 44 healthy controls) across five European centres and examined 54 predetermined bacterial markers. We categorized patients according to the Montreal Classification and calculated the dysbiosis index (DI). Non-parametric tests were used to compare groups and the Bonferroni correction to adjust for multiple comparisons.

    Results: The fluorescent signals (FSSs) for Firmicutes and Eubacterium hallii were lower in inflammatory bowel disease (IBD) vs. symptomatic controls (p<.05). FSS for Firmicutes, Lachnospiraceae, Eubacterium hallii and Ruminococcus albus/bromii were lower, whereas the signal fo rBacteroides Fragilis was higher in UC vs. symptomatic controls (p<.05). FSS was higher for Bifidobacterium spp., Eubacterium hallii, Actinobacteria and Firmicutes among patients with ulcerative proctitis, compared to extensive colitis (p<.05). In CD, we observed no association with disease location. The DI correlated with faecal-calprotectin in both CD and in UC (p<.001). In terms of treatment escalation and anti-TNF response, differences were observed for some bacterial markers, but none of these associations were statistically significant.

    Conclusion: Our data reveal that the GA-map (TM) Dysbiosis Test holds the potential to characterize the faecal microbiota composition and to assess the degree of dysbiosis in new-onset IBD. On the other hand, our results cannot demonstrate any proven diagnostic or predictive value of this method to support clinical decision making.

  • 7.
    Vatn, S.
    et al.
    Akershus University Hospital, Akershus, Norway.
    Karlsson, M. C.
    Genetic Analysis AS, Oslo, Norway.
    Carstens, Adam
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Ersta Hospital, Stockholm, Sweden.
    Detlie, T. E.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Ricanek, P.
    Akershus University Hospital, Akershus, Norway.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
    Lindquist, C. M.
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Jahnsen, J.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Casen, C.
    Genetic Analysis AS, Oslo, Norway.
    Vatn, M. H.
    Oslo University, Oslo, Norway.
    Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S555-S555Article in journal (Other academic)
  • 8.
    Vatn, S.
    et al.
    Akershus University Hospital, Akershus, Norway.
    Karlsson, M. C.
    Genetic Analysis AS, Oslo, Norway.
    Carstens, Adam
    Örebro University, School of Medical Sciences. Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Ersta Hospital, Stockholm, Sweden.
    Detlie, T. E.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Ricanek, P.
    Akershus University Hospital, Akershus, Norway.
    Lindquist, C. M.
    Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
    Bergemalm, Daniel
    Örebro University, School of Medical Sciences. Örebro University Hospital. Department of Gastroenterology.
    Jahnsen, J.
    Akershus University Hospital, Akershus, Norway; Oslo University, Oslo, Norway.
    Halfvarson, Jonas
    Örebro University, School of Medical Sciences. Department of Gastroenterology.
    Casen, C.
    Genetic Analysis AS, Oslo, Norway.
    Vatn, M. H.
    Oslo University, Oslo, Norway.
    Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation2018In: Journal of Crohn's & Colitis, ISSN 1873-9946, E-ISSN 1876-4479, Vol. 12, no Suppl. 1, p. S557-S557Article in journal (Other academic)
1 - 8 of 8
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf